The Effect of Temozolomide Dose and Erythropoietin Combination On Survivin Gene Expression in Human Glioblastoma Cell Lines

Osun A., Erbayraktar Z., Erbayraktar S., Samancioglu A., Zadeogullari Z., Akhisarlioglu S. T., ...Daha Fazla

JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, cilt.29, sa.3, ss.518-526, 2012 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 3
  • Basım Tarihi: 2012
  • Dergi Adı: JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.518-526
  • Anahtar Kelimeler: Erythropoietin, Glioblastoma, Survivin, Temozolomide, PHASE-II TRIAL, RECURRENT, GLIOMA, MULTIFORME, RADIATION, RADIOCHEMOTHERAPY, PHARMACOKINETICS, RADIOTHERAPY, MELANOMA
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Glioblastoma (GBM) is an aggressive primary brain tumor and it is known that prognosis is poor. Because of the infiltration of the tumor cells to the whole brain tissue, surgery is done for decompression and for histopathological diagnosis. Radiotherapy is mandatory after surgery but survival period is not sufficient. In recent years there are many researches for chemotherapeutical agents to use for treatment of GBM but most of the results of the researches are controversial. Temozolomide (TMZ) is a new agent which is effective in prolonging survival of GBM patients. Erythropoietin promotes red blood cell maturation and used to prevent or treat anemia. It is also known that EPO has neuroprotective effect. In this study we used GMS-10 human glioblastoma cell lines. We applied TMZ with different doses and TMZ + EPO combination to check the efficacy on the survivin gene expression in human glioblastoma cell lines. As a result we observed that increasing the dose of TMZ and combination with EPO results over expression of survivin gene which means drug resistance.